Navigate Fool.com
Will BIOL beat
the market?
Community Rating: 2 Stars: Unattractive

2.35 -0.01 (-0.42%)

REAL-TIME: Last trade at

Extended Hours: $2.35 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.37
Previous Close $2.36
Daily Range $2.27 - $2.40
52-Week Range $1.14 - $5.93
Market Cap $87.9M
P/E Ratio -6.94
Dividend (Yield) $0.00 (0.0%)
Volume 144,794
Average Daily Volume 304,895
Current FY EPS $0.00

How do you think BIOL
will perform against the market?

Top BIOL Bull/Bear Pitches


KimLanners (0.4)
Submitted April 6, 2011


1 Replies Reply Report this Post

thefallawayj (< 20)
Submitted July 10, 2007

Biolase is going to have trouble expanding because it only currently sells one product. There is a limited supply that the company can sell to companies.

0 Replies Reply Report this Post

News & Commentary Rss Feed

The Fool Looks Ahead

There's a lot happening in the new week.

Stocks: Insiders Buy at Argos Therapeutics, Biolase, and El Paso Pipeline

Plus, a purchase at Bally Technologies.

Heatlthcare Stocks Inch Onto Positive Ground; BIOLASE Climbs After Canada OKs Its Dental Laser

Sector Update: Healthcare

DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of BIOLASE, Inc. of Upcoming Deadline

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against BIOL

Healthcare Stocks In Retreat; Biolase Up 50%, More Than Recouping Yesterday's Rumor-Fueled Fall To 5

Healthcare Stocks In Retreat; Biolase Up 50%, More Than Recouping Yesterday's Rumor-Fueled Fall To 52 Week Lows

Sector Update: Healthcare

New Stock Coverage: Tesla Motors Inc Is in the Driver's Seat

Three Biotech Giants to Look For

See More BIOL News...




Healthcare Information Services


A medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. Website: http://www.biolase.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks